Aspirin: 19th-Century Drug, 21st-Century Challenges (Insights from the ASPECT Study)



About this Webinar

Date: Tuesday, February 28, 2012

Author: Gurbel, Paul A., MD
Director, Sinai Center for Thrombosis Research
Sinai Hospital of Baltimore
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
Also by this Author 

Category: CE Credit

Description: Paul A. Gurbel, MD, discusses clinical guidelines regarding the use of aspirin for antithrombotic therapy, potential mechanisms for aspirin’s therapeutic benefit as well as resistance to aspirin therapy, the results of the ASPECT clinical trial, and monitoring patients for aspirin resistance.

Learning Objectives:
o Describe platelet reactivity in response to various agonists at 3 different doses of aspirin (eg, 81 mg qd, 162 mg qd, and 325 mg qd) in patients with coronary artery disease
o Differentiate between aspirin’s effects on COX-1 specific and COX-1 non-specific pathways
o Discuss the dose-dependent effects of aspirin and associated clinical implications for patients